Slow Rollout Seen For Elan Tysabri

newratings.com - USA
1015 GMT [Dow Jones] NCB Stockbrokers' Orla Hartford sees a relatively slow rollout for MS drug Tysabri in the US and EU. "It'll ...
See all stories on this topic

Biogen Idec and Elan Announce Availability of Tysabri (Natalizumab ...
DG News - USA
... announced, the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for the reintroduction of Tysabri as a ...

DAILY CHECK-UP
Kentucky.com - Lexington,KY,USA
... said yesterday its multiple sclerosis treatment Tysabri is now available in the United States, 17 months after the companies pulled the drug from pharmacies. ...

Short-term T-bills mixed
San Diego Union Tribune - United States
... Biogen Idec and Elan Corp.'s multiple sclerosis treatment Tysabri returned to the market yesterday in the United States and several European countries. ...

Tysabri returns to market after almost 18 months
Boston Globe - United States
... of Ireland began commercial sales of Tysabri, the promising multiple sclerosis treatment that has been off the market for almost 18 months on concerns about ...

Elan confirms Tysabri's EU prices, which are higher than expected
MarketWatch - USA
PLC (ELN) Tuesday confirmed the prices of multiple sclerosis drug Tysabri in three EU markets, which are higher than market forecasts. ...
See all stories on this topic

Biogen Idec and Elan Announce Availability of TYSABRI(R) and ...
Financial News USA (press release) - La Puente,CA,USA
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc recently announced the commercial availability of TYSABRI® (natalizumab) for the treatment of relapsing ...